PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)

Not Recruiting

Trial ID: NCT04347954


The study aims to determine the safety and efficacy of povidone-iodine (PVP-I) containing nasal sprays as compared to isotonic saline nasal sprays in COVID-19 positive patients. The primary outcome measure is SARS-CoV-2 viral titers in the nasal cavity and nasopharynx. In vitro studies have shown PVP-I to be highly virucidal against the viruses which cause SARS and MERS. Additionally, clinical studies have shown PVP-I saline sprays to be well tolerated in human subjects. PVP-I oral rinses and sprays have been trialed as methods to reduce the incidence and symptoms of viruses which cause the "common cold."

Official Title

Effect of PVP-I Nasal Sprays vs Normal Saline Nasal Sprays on SARS-CoV-2 Nasopharyngeal Titers

Stanford Investigator(s)

Jayakar V. Nayak, MD, PhD
Jayakar V. Nayak, MD, PhD

Associate Professor of Otolaryngology - Head & Neck Surgery (OHNS) and, by courtesy, of Neurosurgery


Inclusion Criteria:

   - Diagnosis of COVID-19 by lab test within 5 days of study participation

Exclusion Criteria:

   - Allergy to "iodine," shellfish, or food dye

   - Receiving intranasal steroids

   - Sinus surgery within 30 days of beginning the study

   - Intubated at the time of enrollment

   - Pregnancy

   - Participation in other COVID-19 studies - to be determined on a case by case basis


drug: Povidone-Iodine 2%

drug: Povidone-Iodine 0.5%

drug: Isotonic saline 0.9%

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Peter H Hwang, MD